RBr042 inhaled for chronic respiratory disease​

Our most advanced drug, RBr042, is an inhaled RNA therapeutic, a 'splice-switching oligonucleotide' or SSO, which inhibits RAGE and increases esRAGE in the lung. esRAGE is a naturally occurring, anti-inflammatory spliceoform of RAGE.

RBr042 is being developed for chronic inflammatory lung diseases, including COPD, in which disease severity correlates with reductions in esRAGE.

​

RBr042 is designed to switch the equilibrium back towards healthy levels of esRAGE, inhibit pro-inflammatory RAGE signalling, and protect the lung against further damage.